Allergic Conjunctivitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Allergic Conjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions.
Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) becomes swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye, and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.
The Allergic Conjunctivitis drugs in development market research report provide comprehensive information on the therapeutics under development for Allergic Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Allergic Conjunctivitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 27 molecules, with 27 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Allergic Conjunctivitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Allergic Conjunctivitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Allergic Conjunctivitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Accolade Pharmaceuticals LLCAldeyra Therapeutics Inc
Alexion Pharmaceuticals Inc
ALK-Abello AS
Allakos Inc
Clevexel Pharma SA
Faes Farma SA
Henan Maiyingnuo Pharmaceutical Technology Co Ltd
IACTA Pharmaceuticals Inc
JW Pharmaceutical Corp
Kissei Pharmaceutical Co Ltd
Nanomerics Ltd
Nexeos Bio
Nitto Medic Co Ltd
Ocumension Therapeutics Co Ltd
OKYO Pharma Ltd
Quark Pharmaceuticals Inc
RAPT Therapeutics Inc
Santen Pharmaceutical Co Ltd
Satellos Bioscience Inc
SIFI SpA
Siolta Therapeutics Inc
Sylentis SAU
Telios Pharma Inc
Vanda Pharmaceuticals Inc
Wuhan Yicheng Biotechnology Co Ltd
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Allergic Conjunctivitis reports